The agency said its booster EUA decision was based on the immunogenicity studies that were submitted.
The US Food and Drug Administration based its decision to authorize booster shots for the Janssen Biotech Inc. vaccine on the submitted data, but it appears a large swath of the package may not be reviewed.
The FDA on 20 October amended the Janssen COVID-19 vaccine emergency use authorization to allow the second shot without a...
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
